Boehringer Ingelheim GMBH is gearing up to collect real-world, comparative data pitting its anticoagulant Pradaxa (dabigatran) against other treatments for stroke prevention in atrial fibrillation, including Johnson & Johnson/Bayer AG’s competing Xarelto (rivaroxaban) and long-time standard of care warfarin, in a massive global trial.
Boehringer’s GLORIA-AF registry program will look at long-term use of antithrombotic treatments for reducing risk of stroke in 56,000 patients...